MedSysEvidence-graded reference

MedSys / Heart & cholesterol / For clinicians

Heart & cholesterol guide · Written for clinicians

Clinical assessment pathway

A four-phase escalation pathway. Opens with a primer on what has changed in lipidology, so it stands alone.

Primer

What has changed in lipidology since most of us trained

This section exists so the pathway below stands on its own. If you order a standard lipid panel and read the LDL-C, none of what follows will be news in principle — but several of these points change what you order and how you interpret it. Each is stated at greater length, in plain language, in the patient chapters. Skip to Phase 1 if it is all familiar.

  1. apoB counts particles; LDL-C weighs what is inside them Strong

    Every atherogenic particle — LDL, VLDL, IDL, Lp(a), chylomicron remnant — carries exactly one apoB-100 molecule, so apoB is a direct 1:1 particle count. LDL-C estimates the cholesterol mass those particles carry between them. When particles are small and cholesterol-depleted, which is the norm in insulin resistance and hypertriglyceridaemia, the same LDL-C represents a considerably higher particle count.

    Discordance between LDL-C and apoB is present in roughly one patient in five — a proportion that, like the equation-discordance figure in chapter 2, moves with the definition and cut-points used — and it runs in the direction of under-estimating risk in precisely the patients whose metabolic risk is highest.

    In practice: add apoB where triglycerides are raised, HDL is low, waist or HbA1c is climbing, or where a reassuring LDL-C does not match the clinical picture in front of you.

  2. The lab probably calculated that LDL rather than measuring it Strong

    Friedewald estimates LDL-C as TC − HDL-C − (TG / 2.2) in mmol/L, assuming a fixed cholesterol-to-triglyceride ratio in VLDL. That assumption degrades as triglycerides rise — conventionally treated as invalid above about 4.5 mmol/L — and it tends to under-estimate LDL-C both at low LDL-C and at high TG. Those are the two situations in which the treatment decision is finest. The Martin–Hopkins and Sampson–NIH equations estimate better in those situations; a direct LDL-C assay removes the equation but not the biological variation, and apoB measures something different again — particle number rather than cholesterol mass, which is the more useful quantity where the two are discordant. None of the three removes the problem entirely.

    In practice: before acting on a borderline LDL-C, check whether it was calculated and what the triglycerides were when the sample was taken.

  3. Remnant cholesterol costs nothing and you already have it Strong

    Remnant cholesterol = TC − LDL-C − HDL-C. It is the cholesterol carried in triglyceride-rich lipoproteins and their remnants, and genetic and observational evidence supports a causal role for it in atherosclerotic disease — a body of evidence that is strong, but not the randomised-trial evidence that underpins LDL-C lowering. It requires no additional test — only a subtraction from the panel already on the screen.

  4. Non-HDL is the workhorse NICE already endorses Strong

    TC − HDL-C. No fasting required, and it captures the cholesterol carried by all apoB-containing lipoproteins rather than LDL alone — a cholesterol mass, not a particle count. NG238 (December 2023, which updates and replaces CG181) frames the primary-prevention treatment response as a greater-than-40% reduction in non-HDL cholesterol; for secondary prevention it sets targets of LDL-C ≤ 2.0 or non-HDL-C ≤ 2.6 mmol/L. The framework differs by context and it is worth not collapsing the two. If one habit changes after reading this, let it be no longer treating LDL-C as the only number on the panel.

  5. Lp(a) is measured once in a lifetime Strong

    Largely genetically determined, essentially stable across adult life, and not meaningfully lowered by statins. Approximately one adult in five is elevated, though the threshold for “elevated” is not standardised across guidelines and the proportion moves with it. An elevated Lp(a) shifts risk upwards independently of LDL-C, strengthens the case for earlier and more intensive apoB lowering, and has implications for cascade screening of first-degree relatives. Not ordering it once is a missed opportunity rather than a saving.

  6. Residual inflammatory risk is a separate axis from residual cholesterol risk Strong

    Two propositions here, graded separately, and the distinction is the whole point. That hs-CRP is an independent marker of residual cardiovascular risk is what the grade above refers to, and it is robust: it identifies patients whose risk persists despite well-controlled apoB. The clinical point is not that we routinely prescribe an anti-inflammatory; it is that a well-treated apoB with a persistently raised hs-CRP is not a fully treated patient.

    Whether lowering it helps is a separate question, and it is currently open. Contested CANTOS (2017) showed canakinumab reduced events without changing lipids, and COLCOT (2019) and LoDoCo2 (2020) showed benefit from colchicine in secondary prevention. Against that: CIRT (2019) was neutral; CLEAR SYNERGY / OASIS-9 (2025, n = 7,062), the largest colchicine trial run, found no reduction in the primary composite despite lowering CRP; and ZEUS (2026, n > 6,300) found that direct IL-6 inhibition with ziltivekimab hit its biomarker targets and returned a hazard ratio of 0.99 (0.88–1.11). Treat measurement and treatment as two different decisions.

    In practice: hs-CRP at baseline, repeated once the obvious confounders (infection, flare, recent injury) are excluded.

  7. The insulin axis belongs inside the lipid workup, not beside it Strong

    The commonest dyslipidaemia in UK primary care is not isolated hypercholesterolaemia. It is the metabolic pattern: raised triglycerides, low HDL, small dense LDL, remnants elevated, and apoB high relative to LDL-C. It is driven by hepatic de novo lipogenesis under chronic hyperinsulinaemia, which is why the pattern responds to carbohydrate load — and sometimes, less consistently, to shortening the eating window — rather than to dietary cholesterol.

    The TG/HDL ratio is a crude but usable surrogate for insulin resistance, with the caveat that it performs less well in patients of Black African or African-Caribbean family origin, where the validating cohorts are largely African-American. HbA1c is part of a lipid assessment, not a separate diabetes question deferred to another appointment.

  8. The causality question is settled, and that matters both ways Strong

    Mendelian randomisation across many independent variants affecting LDL-C and apoB shows that lifelong lower apoB tracks with lower cardiovascular events, with effect proportional to both the magnitude and the duration of exposure. This does not rest on any single trial, and it is the reason the direction of travel is not in serious dispute.

    It cuts both ways. It is the argument for a proper trial of lifestyle in borderline primary prevention, because duration of exposure is what matters and a fifty-year-old has time. It is equally the argument against leaving a genuinely high-risk patient on an open-ended lifestyle trial, because every year of exposure is doing cumulative damage.

  9. What a CAC of zero does and does not tell you Strong

    Zero calcium confers a low short-term event rate and is a defensible reason to defer statin in borderline primary prevention. It does not exclude non-calcified plaque, it is much less informative below roughly age 40, and it can be falsely reassuring where Lp(a) is high or familial hypercholesterolaemia is in play. Above zero, the score establishes that disease is present; it is not a number to chase downwards, since successful treatment often calcifies plaque and raises it.

None of this displaces QRISK3, SCORE2 or NICE guidance, and none of it is an argument for withholding statins from patients who need them. It is an argument for making the decision on complete information rather than on a single calculated LDL-C.

15

For doctors & healthcare professionals

A structured patient assessment pathway built around the modern understanding of residual cardiovascular risk — for time-pressured GPs without lipidology subspecialty training who want to give their patients a more complete picture before initiating statin therapy.

For clinicians

The conventional lipid panel was developed before the modern understanding of residual cardiovascular risk, apolipoprotein-based particle science, and accessible direct imaging via Coronary Artery Calcium (CAC) scoring. The result, in real-world UK general practice, is a workflow where treatment decisions — particularly statin initiation — often rest on a single LDL number and a QRISK3 calculation, without the supporting context that modern lipidology considers standard.

This section is a non-prescriptive, four-phase escalation pathway. Each phase is triggered by what the previous phase reveals — so most patients will never need Phases 3 or 4. The goal is to enable patients to have a structured, evidence-based trial of lifestyle and supplement intervention where appropriate, while clearly identifying the subset for whom statins or specialist referral are non-negotiable. It is also intended to give patients an informed framework for their own consultations — many will read this themselves before raising it with their GP.

For healthcare professionals. This pathway supplements, never replaces, NICE guidance (NG238, NG28), clinical judgement, and validated risk calculators (QRISK3, SCORE2). It is not a diagnostic or treatment protocol. Statins remain extremely effective and life-saving in appropriately selected patients — the goal is appropriate use, not avoidance. Where Phase 3 imaging confirms moderate or severe plaque, or where QRISK3 exceeds 20%, lipid-lowering therapy should not be delayed. This section assumes the clinician will apply their own judgement and refer to specialist lipidology where indicated.
1

Comprehensive baseline panel

When: First lipid abnormality, family history concern, or patient request for fuller workup. Goal: A complete-enough biomarker picture to either reassure or justify escalation, from a single blood draw.

The conventional UK GP lipid panel (TC, LDL, HDL, TG) misses three independent residual-risk axes: actual atherogenic particle count (apoB), residual inflammatory risk (hs-CRP), and lifetime genetic load (Lp(a)). It also misses the secondary causes of dyslipidaemia (thyroid, liver). The panel below adds these, and most are available on the NHS if requested specifically.

Test NHS Rationale
Full lipid panel
TC, LDL, HDL, TG, non-HDL, TC/HDL, remnant-C
Routine Baseline. Calculated remnant cholesterol (TC − LDL − HDL) is now recognised as an independent causal CVD risk factor (Nordestgaard et al., EHJ 2024); standard NHS panels can derive it from the same blood draw without additional cost. Non-HDL captures the full atherogenic-particle cholesterol burden.
Apolipoprotein B Available if requested Gold-standard atherogenic particle count. Resolves the LDL-discordance pattern (numerous small particles with low total LDL-C — the most dangerous lipid phenotype, which routine LDL alone misses). The AMORIS, INTERHEART, and MESA cohort studies all show apoB outperforms LDL as a CVD risk predictor. Add at the same blood draw — most labs run it as a simple immunoturbidimetric assay.
Apolipoprotein A-1
+ ApoB:ApoA-1 ratio
Available if requested When paired with apoB, the ratio is the single best lipid risk metric in INTERHEART (the global case-control study of 15,152 MIs). Target: men <0.7, women <0.6. Once you have apoB, adding apoA-1 is trivial. Particularly useful where lifestyle counselling is being chosen over pharmacology — the ratio improves measurably with diet and exercise within 3 months.
Lipoprotein(a) Available if requested Test once in a lifetime — genetically fixed. ~20% of the UK population carries elevated Lp(a). Drives both lifetime ASCVD and calcific aortic valve disease, independent of LDL. Cannot be lowered by lifestyle. Identifying carriers means treating their modifiable risk factors more aggressively (the only available lever). Cascade testing of first-degree relatives is appropriate if Lp(a) is significantly elevated.
hs-CRP
High-sensitivity C-reactive protein
Routine Residual inflammatory risk axis — independent of lipid burden, and a robust predictor. The 2025 ACC Scientific Statement elevated hs-CRP to a core residual-risk biomarker. Whether lowering it changes outcomes is unsettled: CANTOS (NEJM 2017) reduced events with canakinumab and no lipid change, but CLEAR SYNERGY / OASIS-9 (NEJM 2025) and ZEUS (2026) both lowered CRP as intended with no event reduction — so measure it for risk stratification, not as a treatment target. Standard hs-CRP (not regular CRP) is needed for the <3 mg/L sensitivity range. Repeat 2-week interval if first result >10 mg/L to exclude acute infection.
HbA1c Routine Glycation environment. The 39–48 mmol/mol "prediabetic" band catches arterial damage years before fasting glucose drifts. Even sub-diabetic HbA1c is independently associated with arterial stiffness across all glycaemic strata (EPIC-Potsdam, Birukov et al., 2021). A normal HbA1c does not exclude postprandial hyperinsulinaemia.
Fasting insulin + HOMA-IR Hard to access — usually requires endo referral or private The single highest-value addition where HbA1c is normal but TG/HDL is elevated. Hyperinsulinaemia frequently precedes HbA1c abnormality by years. HOMA-IR = (fasting insulin × fasting glucose) / 22.5; values >2.5 suggest insulin resistance. Often the only test that catches reactive hypoglycaemia / postprandial insulin patterns that drive atherogenic dyslipidaemia (high TG, low HDL, small dense LDL) before the standard panel reflects the dysfunction.
Homocysteine Available if requested Independent vascular wall damage driver. Particularly worth checking when Lp(a) is elevated, when there is premature cardiovascular family history, or when B12/folate status is uncertain. Levels above 10 µmol/L respond to TMG (trimethylglycine) and B-vitamin supplementation. Untreated hyperhomocysteinaemia is a quietly common contributor to unexplained CV risk.
TSH
+ free T4 if abnormal
Routine Subclinical hypothyroidism is a major secondary cause of dyslipidaemia. Reduces LDL receptor expression on the liver, causing cholesterol to back up in the bloodstream. Statins given in untreated hypothyroidism significantly increase the risk of myopathy — treating the thyroid first often resolves the lipid abnormality without lipid-lowering therapy. Should be standard before any statin discussion in an otherwise asymptomatic patient.
Liver panel
ALT, AST, GGT, ALP
Routine Baseline before any statin discussion, but also screens for MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease, formerly NAFLD). MASLD is mechanistically tied to the same insulin resistance driving the lipid abnormality and is now estimated to affect ~30% of UK adults. Elevated ALT in the context of elevated TG and low HDL is the classic biochemical signature.
U&Es + eGFR Routine Renal function baseline before any pharmacological lipid lowering. Statins, fenofibrate, and bempedoic acid all require dose adjustment in renal impairment. CKD is itself a major independent CV risk amplifier.
2

Imaging triage when Phase 1 is abnormal

When: Two or more Phase 1 axes elevated, QRISK3 borderline (10–20%), or family history of premature CVD with abnormal biomarkers. Goal: Confirm whether biomarker abnormalities have translated to vessel-level disease, using low-cost low-radiation tools before committing to CT.

Phase 2 tests are non-invasive, involve no or minimal radiation, and are widely available privately at modest cost. They serve as a triage layer: if all three are clean, Phase 3 imaging may be deferable; if any reveal disease, Phase 3 becomes warranted.

Investigation UK availability Rationale
Carotid ultrasound
CIMT + plaque assessment
Private ~£150–250
NHS rare without symptoms
Non-invasive, no radiation. Measures Carotid Intima-Media Thickness AND identifies plaque (both calcified and soft) in the carotid arteries. Particularly valuable in younger patients (<50) and women, where coronary atherosclerosis may not yet have calcified and CAC alone would underestimate burden. CIMT >0.9mm or any plaque is significant. See the CIMT × CAC complementarity callout below for the critical caveat about CAC=0 patients.
Resting 12-lead ECG Routine in most GP practices Baseline cardiac rhythm and conduction. Detects LVH, prior silent infarct, conduction abnormalities. Should accompany any cardiovascular workup. Free in NHS practice.
Ambulatory BP monitoring
24-hour ABPM or 7-day HBPM
NICE standard If a single in-clinic reading is borderline, 24-hour ABPM is the NICE-recommended diagnostic standard for hypertension (NG136). Frequently reclassifies "borderline hypertensive" patients in both directions — both confirming sustained hypertension and identifying white-coat effect. Should be done before any new anti-hypertensive initiation in non-emergency cases.
3

Definitive imaging — is plaque present?

When: Phase 1 abnormal AND Phase 2 abnormal, OR Phase 1 strongly abnormal with QRISK3 ≥20%, OR ahead of any committed statin decision in a borderline patient who wants imaging-based confirmation. Goal: Direct measurement of plaque burden — the answer to "do I actually have arterial disease?"

Phase 3 imaging is the highest-value diagnostic step in modern cardiovascular risk stratification. A CAC of zero in a borderline patient is one of the strongest pieces of evidence in cardiology that statin initiation may be safely delayed (the "power of zero"). Conversely, a CAC of 100+ confirms active disease regardless of how the biomarkers look, and is a clear indication for pharmacological lipid lowering.

Investigation UK availability Rationale
CT Coronary Artery Calcium (CAC) scan Private £200–400
NHS limited; some preventive cardiology clinics
The single highest-value test for the "does this patient need a statin?" question. Non-contrast CT, ~1 mSv radiation (less than a routine mammogram), <10 minutes. Result is an Agatston score: 0 = "power of zero" (essentially no calcified plaque, 5–10 year event risk ≈ population baseline); 1–99 = mild; 100–399 = moderate (pharmacology routinely warranted); ≥400 = severe (aggressive management). MESA, CONFIRM, and the Heinz Nixdorf Recall study all demonstrate CAC outperforms QRISK3 and SCORE2 for individual-patient discrimination. See the complementarity callout below for the important CAC=0 caveat in younger patients.
CT Coronary Angiography (CCTA) Private £500–800
NHS via cardiology referral
Adds contrast and visualises the coronary lumen directly — detects both calcified AND non-calcified (soft) plaque, plus stenosis severity. Higher radiation than CAC (~3–10 mSv) but is the imaging gold-standard short of invasive angiography. Particularly useful where CAC is zero but clinical suspicion remains high (younger patients, women, strong family history), or where chest-pain syndromes need exclusion. The SCOT-HEART trial (NEJM 2018) showed CCTA-guided management reduced MI by 41% at 5 years compared with standard care.
Echocardiogram NHS via cardiology referral
Private £200–400
Indicated when: Lp(a) significantly elevated (calcific aortic valve disease risk — Lp(a) is uniquely causal here); LVH suggested on ECG; exercise tolerance reduced or anginal symptoms; suspected diastolic dysfunction in older patients with hypertension. Assesses chamber sizes, valve function, and ejection fraction. Not routine unless there is a specific structural concern.
4

Genetic & specialist workup — complex or unexplained cases

When: Premature CVD (men <55, women <65) without obvious lifestyle cause, severely elevated LDL despite optimal lifestyle and statin therapy, strong first-degree family history of premature MI or sudden death, extreme Lp(a) (>250 nmol/L), or unexplained mixed dyslipidaemia in a normal-weight patient. Goal: Identify the small but clinically critical subset for whom routine pathways will miss the diagnosis.

Most patients never need Phase 4. The patients who do — typically those with monogenic familial hypercholesterolaemia (FH, ~1 in 250 in the UK and frequently undiagnosed), polygenic familial combined hyperlipidaemia, or type III dysbetalipoproteinaemia (ε2/ε2 APOE) — benefit substantially when the diagnosis is established, both for their own treatment intensity and for cascade testing of relatives. The clinical message is that an unusual pattern should trigger referral, not repeated lifestyle counselling that will not work for these patients.

Investigation UK availability Rationale
FH genetic panel
LDLR, APOB, PCSK9
NHS via lipid clinic if Simon Broome / DLCN criteria met; private £300–500 Diagnostic for monogenic familial hypercholesterolaemia (FH). Indication: LDL persistently >5.0 mmol/L (adult) or >4.0 (child) despite lifestyle measures, with family history of early CVD or tendinous xanthomata. Definite or probable FH per Simon Broome criteria mandates NHS lipid clinic referral and enables cascade genetic testing of first-degree relatives, identifying carriers years before they develop disease. Underdiagnosis in the UK is estimated at ~85% — recognising FH is one of the highest-impact things a GP can do.
APOE genotyping Private only ~£100–150 Identifies ε2/ε2 (Type III dysbetalipoproteinaemia: distinctive elevated TG and TC with disproportionately low LDL — highly responsive to carbohydrate restriction and fibrates) and ε4/ε4 (strongest single-gene driver of LDL-sensitivity to saturated fat — these patients respond MORE to Mediterranean diet, not less). Not currently NHS standard but readily available from Medichecks, Atlas Biomed, and ancestry-test add-ons. Useful when conventional lifestyle counselling is producing unexpected (or no) response.
Lp(a) cascade testing
First-degree relatives
Available if requested If index patient has Lp(a) >125 nmol/L, first-degree relatives have a ~50% chance of also being affected. Testing is the same simple blood assay as the index patient and enables early identification of asymptomatic carriers in their 30s and 40s — when modifiable risk factor control has the greatest lifetime impact. Particularly important if there is family history of MI before age 60 or stroke before age 65.
Polygenic risk score (PRS)
CAD-specific PRS
Private/research only ~£100–200 Captures cumulative effect of hundreds of small-effect genetic variants — risk that single-gene FH testing misses. Clinical utility is still emerging but increasingly validated. Identifies "monogenic-negative but polygenic-positive" patients — typically those with strong family history of CVD where standard FH genetics return negative. Not yet NHS standard; best reserved for research or specialist contexts.
Specialist lipid clinic referral NHS via GP referral
Waits vary by region
Indicated when: genuine statin intolerance (true muscle pain confirmed by N-of-1 re-challenge and creatine kinase rise, not nocebo); patient meets criteria for a PCSK9 monoclonal antibody — alirocumab or evolocumab, TA393/TA394, typically LDL >3.5 mmol/L on maximum tolerated statin in established CVD, or >5.0 in high-risk primary prevention, and specialist-initiated, so this is a referral trigger. Inclisiran is a separate question and not by itself a reason to refer: TA733 criteria are prior cardiovascular events with LDL-C persistently ≥2.6 mmol/L on maximum tolerated therapy, and it is initiable in primary carethe full eligibility table is here; confirmed or strongly suspected FH; rare lipid disorders (lipoprotein lipase deficiency, lecithin-cholesterol acyltransferase deficiency); when standard pathways have failed and the patient remains uncontrolled. Lipid clinics also have access to specialist tests (advanced NMR-based lipid subfractionation, LDL receptor functional assays) unavailable in primary care.

Why CIMT and CAC are complementary, not interchangeable

A common clinical assumption is that a CAC score of zero "rules out" coronary artery disease. This is true for calcified plaque only, and the implication that a clean CAC excludes all atherosclerosis is incorrect — with important consequences for younger patients and women in particular.

Both CIMT (Carotid Intima-Media Thickness) and CAC are well-established non-invasive surrogate markers for systemic atherosclerosis, and the two measures are correlated — a high burden in one arterial bed strongly suggests disease in the other (Zaid et al., Journal of Atherosclerosis and Thrombosis, 2017; Pathakota et al., Indian Heart Journal, 2020). However, they measure different things and excel at predicting different outcomes:

  • CAC score detects calcified (hardened) plaque in the coronary arteries directly. It is the significantly stronger predictor of coronary events (heart attacks) per the MESA cohort study (Gepner et al., JAHA, 2017) — because it looks directly at the arteries supplying the heart.
  • Carotid ultrasound detects both calcified and non-calcified (soft) plaque, plus general arterial wall thickening (CIMT). The MESA analysis found CIMT/plaque to be roughly equivalent to CAC for predicting stroke risk — because the carotids supply the brain directly.
The CAC=0 caveat that matters clinically: Lester et al. (Atherosclerosis, 2009) investigated young-to-middle-aged patients with a CAC score of exactly zero. 47% of them still exhibited evidence of subclinical carotid atherosclerosis on ultrasound. CAC sees only calcified plaque — and in younger patients and women, soft (non-calcified) plaque often hasn't had time to mineralise. A clean CAC in these populations can produce false reassurance.

Practical implication: In patients under approximately 50, in women, in those with elevated Lp(a), and in those with strong family history of premature CVD, carotid ultrasound is a useful complement to CAC — not a replacement. In older patients (typically over 55–60) with established lipid abnormalities, CAC alone is generally sufficient for the calcified-plaque burden assessment that drives statin decisions. The two tests are not redundant; they are sequential layers of information about different stages and types of the same disease.

Primary references: Gepner AD, Young R, Delaney JA, et al. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. JAHA. 2017;6(9). · Lester SJ, Eleid MF, Khandheria BK, Hurst RT. Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clin Proc. 2009;84(3):229–233. · Zaid M, Fujiyoshi A, Kadota A, et al. Coronary artery calcium and carotid artery intima-media thickness and plaque: clinical use of these measures for cardiovascular prevention. J Atheroscler Thromb. 2017;24(3):227–239. · Pathakota S, et al. Correlation of coronary artery calcium score with carotid intima-media thickness in Indian patients. Indian Heart J. 2020.

When a non-statin trial period is reasonable first-line

This decision framework is split into two matrices. Most UK patients in the borderline-decision zone will not have CAC imaging at the point of consultation — NHS access is limited and ~£250–400 privately. The first matrix below covers the biomarker-only decision pathway, which is what most GPs actually face. The second matrix covers the more granular CAC-informed pathway, which becomes available once imaging has been done. If CAC is available, it supersedes the biomarker-only matrix — direct measurement beats inference.

Matrix A — Biomarker-only decision pathway (no CAC available)

For patients where CAC imaging is not feasible or has not yet been performed. Uses Phase 1 biomarker pattern + QRISK3 + age/sex modifiers. The thresholds are deliberately more conservative than the CAC-available pathway, because biomarker inference cannot rule out existing plaque the way CAC can.

Patient profile Reasonable approach Reassessment point
All biomarkers optimal, QRISK3 <10%, no family history of premature CVD No intervention beyond lifestyle counselling. Annual lipid + HbA1c recheck. Patient may benefit from baseline apoB and Lp(a) (one-off) for completeness. Annual review
1 axis borderline (LDL 3.4–4.1, OR TG/HDL elevated, OR HbA1c 39–48, OR hs-CRP 1–3), QRISK3 <10%, no premature family history 6–12 months intensive lifestyle — Mediterranean diet, exercise 150+ min/week, sleep, targeted supplements (omega-3, soluble fibre, plant sterols, berberine if metabolic axis). Document baseline and treatment plan in notes. Recheck full Phase 1 panel at 6 months
1 axis borderline, QRISK3 10–20% 3–6 months lifestyle trial with structured supplement protocol — shorter window because background risk is higher. Consider proceeding to Phase 2/3 imaging (carotid US, CAC) at the reassessment if no biomarker improvement, to inform the next step. Reassess at 3 months; escalate to imaging or low-dose statin if biomarkers static
2+ axes elevated (e.g. high LDL + elevated TG/HDL + raised hs-CRP), QRISK3 <10% 3-month lifestyle trial with explicit statin discussion — multi-axis elevation indicates active plaque-forming biology even at low absolute risk. Patient should be informed that this is the "biomarkers say yes, age says wait" scenario where CAC imaging would be particularly informative if accessible. 3-month recheck; strong case for CAC if available
2+ axes elevated, QRISK3 10–20% Short lifestyle trial (8–12 weeks) with statin offer at start. Many patients will accept a brief evidence-based lifestyle window if it is framed as "test the biology first" rather than "statin avoidance." Document the trial. Reassess at 8–12 weeks; default to statin if no meaningful biomarker change
2+ axes elevated, QRISK3 ≥20% Statin initiation per NICE NG238 alongside lifestyle. The combined biomarker burden + absolute risk crosses the threshold where lifestyle trial is no longer the right first step. Patient still benefits from intensive lifestyle alongside. Standard NICE monitoring
LDL persistently >4.9, OR TC >7.5, regardless of QRISK3 Statin without prolonged delay. These thresholds are NICE NG238 indicators for primary-prevention statin initiation independent of QRISK3, particularly with family history. Investigate for FH (Simon Broome / DLCN criteria) — if criteria met, refer to lipid clinic. Recheck lipids 8 weeks; investigate FH if indicated
Lp(a) >125 nmol/L regardless of other findings Aggressive control of modifiable axes. Lifestyle alone cannot lower Lp(a). Lower the LDL target by ~30% from population norms via lifestyle + statin earlier than QRISK3 alone would suggest. Cascade-test first-degree relatives. Echocardiogram if Lp(a) >250 (calcific AV disease risk). Annual lipid review; lifelong management
FH suspected (LDL >5.0 adult / >4.0 child, family history of early CVD, possible xanthomata) Statin without delay per NICE CG71. Refer to lipid clinic for genetic testing (LDLR/APOB/PCSK9) and cascade screening of first-degree relatives. Lifestyle remains essential but is alone insufficient in monogenic FH. Lipid clinic referral mandatory
Premature CVD in first-degree relative (<55 men, <65 women) regardless of biomarkers Lower threshold for both imaging and pharmacology. Family history is an independent risk modifier not fully captured in QRISK3. CAC scan and/or Lp(a) testing particularly informative here. Patient should be considered as having effectively one risk-band higher than their biomarker pattern suggests. Earlier and more intensive monitoring
Matrix B — When CAC imaging is available

When direct imaging has been done (privately or NHS), it supersedes the biomarker-only matrix above. CAC=0 in the right patient is one of the strongest non-treatment arguments in cardiology; CAC ≥100 forces the conversation in the other direction regardless of biomarker pattern.

Patient profile Reasonable approach Reassessment point
CAC = 0, biomarkers borderline (1 axis elevated), QRISK3 <10% 6–12 months intensive lifestyle — Mediterranean diet, exercise, sleep optimisation, targeted supplements (omega-3, fibre, plant sterols, berberine if relevant) Recheck full Phase 1 panel at 6 months
CAC = 0, biomarkers borderline, QRISK3 10–20% 3–6 months lifestyle trial with structured supplement protocol; document baseline carefully Earlier reassessment at 3 months; consider CCTA if biomarkers fail to improve
CAC = 0 in younger patient (<50) or woman, with elevated biomarkers Add carotid ultrasound before treating CAC=0 as fully reassuring (Lester 47% caveat); lifestyle trial reasonable if carotid also clean Carotid US result determines next step
CAC = 0, biomarkers strongly elevated (2+ axes), QRISK3 >20% Lifestyle PLUS likely statin — biomarker burden is high enough that the calcification window is shorter than the natural CAC lag time Statin discussion with patient now, not later; CCTA if patient resistant to medication
CAC = 1–99, any biomarker pattern Combined approach — lifestyle AND likely pharmacology; the plaque-forming machinery is already active. Discuss statin based on QRISK3, age, and patient preference. Consider low-dose first to optimise tolerability. Recheck lipids 8 weeks after initiation; LFTs at 3 months
CAC = 100–399, any biomarker pattern Statin routinely recommended regardless of QRISK3 — imaging confirms moderate plaque. Continue lifestyle but do not delay pharmacology. Consider low-dose aspirin discussion depending on bleeding risk. Standard statin monitoring (8-week lipid recheck, 3-month LFT)
CAC ≥ 400, any biomarker pattern High-intensity statin standard; consider a PCSK9 add-on if LDL targets are not met — inclisiran can be started in primary care under TA733, the monoclonal antibodies need specialist initiation; aspirin discussion; referral for stress testing or CCTA to assess soft plaque burden Cardiology referral appropriate
Recognising statin intolerance — presentations that don't fit the standard pattern

The conventional GP mental model of statin intolerance is dominated by skeletal muscle pain with or without CK rise. This pattern is real, but it captures only a fraction of the genuine intolerance presentations. A persistent clinical problem is that patients presenting with non-muscle symptoms are often dismissed as "not statin-related" — particularly when their ECG, CK, troponin, and routine bloods all look normal — and the statin is continued, sometimes through multiple brand switches, until the symptoms become unignorable or end-organ damage develops.

The presentations below are all documented in the peer-reviewed literature. Most are uncommon individually, but collectively they account for a meaningful proportion of true intolerance. The unifying clinical principle: if a patient reports a new, persistent, statin-temporally-related symptom that affects daily life and resolves on washout, that is intolerance — regardless of whether the standard screening tests are abnormal.

Muscle — the classic
Myalgia, weakness, cramps, exercise intolerance

The pattern most GPs recognise: bilateral, proximal, often worse with exercise, may improve with rest. CK is often normal — a normal CK does not rule out muscle-related intolerance. Decreased exercise capacity in a previously fit patient is the underappreciated form. Resolves typically within 2–4 weeks of withdrawal.

Cardiac — uncommon but serious
Pericarditis & myocarditis

Documented though rare. Classic pericarditis features: positional chest discomfort worse when supine or leaning forward, worse lying on the left side, exercise intolerance, sometimes a pericardial rub. ECG can be entirely normal in early or mild cases — particularly in the absence of the textbook ST elevation. Statin-induced myocarditis can present with elevated troponin without ischaemia, decreased exercise tolerance, or shortness of breath. If symptoms persist or are red-flag, request cardiac MRI — it is the diagnostic standard for both conditions and will see inflammation a normal ECG misses.

Cognitive
"Brain fog", memory difficulty, impaired clarity

Subjective cognitive slowing, difficulty with word-finding, impaired concentration. AHA Scientific Statement explicitly lists cognitive complaints as a recognised but disputed adverse event. Lipophilic statins (atorvastatin, simvastatin, lovastatin) cross the blood-brain barrier more readily than hydrophilic ones (rosuvastatin, pravastatin) — switching class can sometimes resolve cognitive symptoms when muscle tolerance is otherwise fine.

Neurological
Peripheral neuropathy

Burning, numbness, or tingling in the extremities — typically distal and symmetrical. One cohort showed statin users had ~4× the overall and ~16× the definite peripheral neuropathy risk vs. controls, with risk scaling with dose and duration. Often misattributed to early diabetic neuropathy or B12 deficiency; worth considering statin causation when those common causes have been excluded.

Sleep / mood
Disturbed sleep, irritability, mood change

New-onset insomnia, fragmented sleep, vivid or disturbing dreams. Some patients report increased irritability or aggression — small but real signal in pharmacovigilance data. Often dismissed because patients (and doctors) don't initially connect a sleep problem to a cholesterol drug. Worth asking directly if the temporal pattern fits.

Hepatic / metabolic
Persistent ALT rise, new dysglycaemia

Modest ALT rise (1–3× ULN) is common and usually settles; persistent or progressive rise warrants investigation. New impaired fasting glucose or HbA1c drift following statin initiation is a recognised pharmacological effect (the diabetogenic effect of statins is real but modest in absolute terms; benefit usually outweighs in established CVD). In a patient who was metabolically healthy before statin initiation and has drifted into prediabetic range, the statin is on the list.

Autoimmune — rare
HMGCR-positive immune-mediated necrotising myopathy

Severe progressive proximal weakness, markedly elevated CK (typically >10× ULN), positive anti-HMGCR antibodies. Critically — this condition does NOT resolve on statin withdrawal and requires specific immunosuppressive therapy. If a patient continues to deteriorate after statin cessation, this is the diagnosis to consider. Refer to rheumatology and lipid clinic. May coexist with cardiac myositis (statin-associated cardiomyopathy / SACM) — cardiac MRI indicated if cardiac symptoms.

Other
Tendinopathy, erectile dysfunction, mouth ulcers, alopecia

Less common but reported. Achilles tendinopathy in particular has signal in pharmacovigilance data. None of these would individually be sufficient to discontinue an indicated statin, but each is worth considering when a temporal pattern is clear and other causes have been excluded.

The clinical principle most easily missed: A patient's reported symptom can be statin-related even when the standard screening tests (CK, troponin, ECG, LFTs) are all normal. The screening tests have low sensitivity for the rarer presentations — pericarditis particularly, where ECG can look normal in early disease, and where cardiac MRI is the only tool that reliably demonstrates the inflammation. If a patient describes a new, persistent, daily-life-affecting symptom that began within 1–8 weeks of statin initiation (or brand switch), and the symptom dimension is plausibly recognised in the literature — believe the patient and trial a washout. Forcing continuation through brand switches and dose changes in the face of consistent reported symptoms is how rare adverse effects progress to end-organ damage.
A note on cross-intolerance to ezetimibe. The mechanisms of statin intolerance (HMG-CoA reductase inhibition, mitochondrial effects, HMGCR autoimmunity) and ezetimibe intolerance (NPC1L1 transporter inhibition) are pharmacologically distinct. True cross-intolerance between the two should be rare. In practice however, a subset of statin-intolerant patients also report intolerance to ezetimibe — particularly those whose original statin reaction involved cardiac, autoimmune, or systemic-inflammatory features rather than straightforward myalgia. Whether this represents shared idiosyncratic immune response, accumulated drug-class sensitisation, or unrelated symptoms with similar reporting bias is not fully resolved. The practical implication is the same: if a patient cannot tolerate ezetimibe after statin intolerance, escalate to the alternative-mechanism agents (bempedoic acid, PCSK9 inhibitors, inclisiran, icosapent ethyl) — none of which share statin or ezetimibe biochemistry — rather than insisting on retrial.

What the blinded evidence actually shows — the numbers to have to hand

The section above lists a wide range of presentations because they are documented and because missing a real one matters. Read alone, it would give a misleading impression of how often statins cause symptoms. These are the counterweight figures, and they are worth knowing precisely rather than approximately — a patient who has read something frightening online is not reassured by "it is probably nothing".

CTT Collaboration, Lancet 2022;400:832–845. Individual participant data from 19 double-blind placebo-controlled trials, 123,940 participants, weighted median 4.3 years. Muscle pain or weakness reported by 27.1% on statin versus 26.6% on placebo — RR 1.03 (1.01–1.06). In year one, RR 1.07 (1.04–1.10), an absolute excess of 11 events per 1,000 person-years (6–16). That works out at roughly one in fifteen muscle-symptom reports among statin-takers being attributable to the statin. After the first year there was no significant excess at all.
SAMSON, NEJM 2020 / JACC 2021;78:1210–22. Sixty patients who had already stopped a statin for side effects, randomised across atorvastatin, placebo and no-tablet months. Mean symptom scores: statin 16.3, placebo 15.4, no tablet 8.0. The no-tablet arm is what makes this trial decisive — it shows the placebo symptoms were actively produced by taking a tablet rather than being background noise. Nocebo ratio 90% — and that figure needs saying precisely, because the shorthand it invites is wrong. It does not mean 90% of patients had no real side effect. It means 90% of the excess symptom burden produced by taking a tablet at all, relative to the no-tablet months, was reproduced by placebo. Early cessation 21.6% on statin, 17.2% on placebo. Half restarted a statin successfully after being shown their own data.
StatinWISE, BMJ 2021;372:n135. A series of N-of-1 trials in UK primary care, atorvastatin 20 mg against placebo. Mean difference in symptom score −0.11 (95% CI −0.36 to 0.14). Two-thirds resumed the statin or intended to. This is the UK primary-care replication, which matters when discussing it with a UK patient.
ASCOT-LLA, Lancet 2017;389:2473–81. The natural experiment. Excess muscle-related adverse events appeared in the non-blind extension phase and not in the blinded randomised phase of the same trial, in the same patients. Knowing you are taking a statin is what produced the excess.
The counter-argument, stated fairly. Contested Critics — Thompson among them — argue that N-of-1 designs with one-month blocks may be too short for symptoms with a longer onset, that patients who agree to rechallenge are self-selected toward mild cases, and that group means can hide a genuinely affected minority. That is a reasonable objection to over-reading these trials. It is not a reason to skip a rechallenge: the design that settles it for an individual patient is the same one either way.
What this changes in the consultation. Not the validity of the symptom — nocebo symptoms are real symptoms, and telling a patient their pain is imaginary is both wrong and counterproductive. What it changes is the next step: the prior probability that a specific statin at a specific dose is causing a specific symptom is low enough that structured rechallenge is worth doing before abandoning a class of drug with this much outcome evidence behind it. Framed as "let us find out whether it is this drug" rather than "let us see if you were imagining it", roughly half to two-thirds of patients end up back on treatment.
When to check CK, and when not to. Routine CK monitoring in an asymptomatic patient is not indicated and generates more confusion than information. Check it when symptoms are severe, when there is objective proximal weakness, when symptoms persist after stopping, or where rhabdomyolysis is a genuine consideration. A normal CK during a symptomatic episode argues against myopathy, but does not exclude statin-associated muscle symptoms — most occur with an entirely normal CK, which is the single most useful thing to know before ordering one. The pattern that should prompt escalation is different: CK elevation and progressive proximal weakness that persist or worsen after the statin is stopped, particularly above ten times the upper limit. That combination raises HMGCR-antibody immune-mediated necrotising myopathy — covered above, and the one presentation where rechallenge is contraindicated rather than encouraged.
Before concluding intolerance, exclude an interaction. Simvastatin and atorvastatin are CYP3A4 substrates, so their exposure rises with clarithromycin, itraconazole, ritonavir, diltiazem, verapamil, amiodarone, ciclosporin and grapefruit juice — and simvastatin is the most vulnerable of the group. Rosuvastatin and pravastatin are largely not CYP3A4-dependent, which is one reason a switch sometimes resolves what looked like class intolerance. SLCO1B1 variants impair hepatic statin uptake and raise systemic exposure, most markedly for simvastatin; pharmacogenomic testing is discussed in the genetics chapter. An interaction that is dose-dependent and reversible is a different problem from intolerance, and it is commoner.
Statin intolerance — the escalation ladder

Statin intolerance is genuinely heterogeneous. True pharmacological intolerance is less common than nocebo response (the SAMSON trial famously showed ~90% of symptoms are non-specific), but it does exist — and a small subset of "statin-intolerant" patients are also intolerant to ezetimibe, despite ezetimibe acting via a completely different mechanism (NPC1L1 transporter, not HMG-CoA reductase). The ladder below covers each escalation step.

Scenario Reasonable approach Reassessment / referral
Reported statin intolerance — first episode Confirm before substituting. 8-week washout. SAMSON-style N-of-1 re-challenge with placebo and active arms if practical, or sequential trial of 2–3 different statins (rosuvastatin → atorvastatin → pravastatin) at low doses with 6-week washouts between. Check CK levels during symptomatic episodes — a normal CK during pain suggests nocebo rather than myopathy. Many patients tolerate a different statin at low dose without recurrence. Most "intolerant" patients eventually tolerate one statin at one dose
Confirmed intolerance to 2+ statins at lowest doses Ezetimibe 10mg monotherapy — different mechanism (intestinal cholesterol absorption via NPC1L1), no shared toxicity with statins in principle. Typically lowers LDL ~18–20%. Well-tolerated in the vast majority of statin-intolerant patients. Add intensive lifestyle + soluble fibre to maximise effect. Recheck lipids 8 weeks; if LDL still well above target, proceed to next step
Statin-intolerant AND ezetimibe-intolerant (rare but real ~3–5% of statin-intolerant) Refer to lipid clinic. Next-line agents have entirely different mechanisms from both statins and ezetimibe:
Bempedoic acid (ACL inhibitor — liver-selective, no skeletal muscle exposure, reduces LDL ~17–22%; well-tolerated in statin-intolerant cohorts per CLEAR Outcomes trial)
PCSK9 inhibitors (alirocumab, evolocumab — monoclonal antibodies, fortnightly injection, reduce LDL ~60% and Lp(a) ~20–25%; NICE-funded for FH and established CVD with persistent LDL elevation)
Inclisiran (siRNA targeting PCSK9 mRNA — 6-monthly injection after initial loading; same LDL effect as monoclonal PCSK9 inhibitors with much simpler dosing schedule)
Icosapent ethyl (high-dose pure EPA — REDUCE-IT showed event reduction independent of LDL change, particularly useful where TG persistently elevated)
None of these share the proposed mechanisms of statin or ezetimibe intolerance.
Lipid clinic mandatory; agents above are specialist-initiated
Intolerance with documented CK rise >10× ULN or rhabdomyolysis Urgent cessation, rule out underlying myopathy. Check thyroid status (hypothyroidism amplifies statin myopathy risk), vitamin D, CoQ10 status. Investigate for genetic predisposition (SLCO1B1 variants particularly with simvastatin). Specialist-led management thereafter for the PCSK9 monoclonal antibodies — though inclisiran is commissioned for primary care initiation, which is the commonest gap in practice as the next pharmacological line. Urgent referral; not GP-managed
Multi-drug intolerance with no documented biochemical abnormality Consider the nocebo-response evidence base honestly with the patient. The SAMSON and StatinWISE trials demonstrated that the majority of reported statin symptoms recur with placebo. A frank conversation including showing the patient these data sometimes enables a re-trial. If patient remains adamantly intolerant after this, refer to lipid clinic — the alternative-agent armamentarium remains open, and CV risk cannot be ignored. Lipid clinic; lifelong alternative agent management
The underlying principle across both matrices: CAC-confirmed plaque (≥100) is the strongest single argument for pharmacology; CAC=0 in an older patient is the strongest single argument for delaying it. In the absence of CAC, the biomarker pattern plus QRISK3 plus family history provide the framework — but with a deliberately more conservative bias, because inference cannot rule out the disease that direct imaging would have caught. Lifestyle and pharmacology are not alternatives — they are complementary, and in any patient with established plaque (CAC ≥1) or QRISK3 ≥20%, both are required. The non-statin trial period is appropriate in borderline cases — it is not appropriate when the evidence threshold for pharmacology has already been crossed.

Two self-supplementation interactions worth screening for

When: Any statin review, medication reconciliation, or workup of unexplained myalgia, raised CK, or new palpitations. Goal: Catch two common over-the-counter supplements that intersect directly with decisions made in this pathway — disclosed rather than discovered.

Patients increasingly arrive already taking metabolic supplements they have read about online. Two are worth asking about by name.

Berberine + statins. Berberine (marketed as "nature's Ozempic" / a natural statin) inhibits CYP3A4, CYP2D6 and P-glycoprotein in humans, so it can raise plasma concentrations of CYP3A4-metabolised statins (simvastatin, atorvastatin, lovastatin) and increase the risk of myopathy and rhabdomyolysis, with possible additive QT-prolonging effects. This is not an absolute bar to co-prescription — berberine has been deliberately combined with statins for additive LDL-lowering in trials — but it should be disclosed and managed, not discovered. Ask about it in any statin review and in unexplained myalgia or raised CK. Where a patient wishes to take both, a statin less dependent on CYP3A4 (rosuvastatin, pravastatin, pitavastatin) with symptom and CK monitoring is more sensible than casual co-administration. Absolute contraindication in pregnancy and breast-feeding (placental transfer; neonatal kernicterus via bilirubin displacement). For context, berberine's lipid evidence base is low-quality and there are no cardiovascular-outcome data — it is not a statin substitute, and a patient attempting to self-treat a genuine statin indication with it should be advised accordingly.
High-dose marine omega-3 + atrial fibrillation. The triglyceride-lowering tiers recommended elsewhere in this tool (≈1.4–4 g/day EPA + DHA) fall in the dose range where RCTs show a dose-dependent increase in incident AF: pooled trial data show roughly a 12% relative increase at ~1 g/day rising to ~50% at 1.8–4 g/day, and the most recent 34-trial meta-analysis (n≈114,000) found a significant signal (OR ≈1.48, absolute risk difference ~0.8%) specifically in higher-CVD-risk patients taking >1.5 g/day. Dietary oily-fish intake (~250–700 mg/day) is, by contrast, associated with lower AF risk. For patients on supplemental EPA + DHA above ~2 g/day — and certainly at the ≈2.8–4 g/day triglyceride tiers — consider an Omega-3 Index (red-cell EPA + DHA; target ~8–12%) to titrate to the lowest dose that reaches target rather than fixed high-dose use, ask about palpitations, and keep a lower threshold for an ECG. The FDA regards ≤3 g/day total (and ≤2 g/day from supplements) as the GRAS ceiling; 4 g/day is prescription-strength dosing (e.g. icosapent ethyl) and should be supervised.
A note on patient autonomy. Many patients reading this section will have already worked through their own biomarker pattern in the rest of this tool. They will arrive at the consultation with informed questions about apoB, Lp(a), TG/HDL ratio, hs-CRP, and CAC scoring — and a clear preference, where the evidence permits, for trialling lifestyle and supplement intervention before initiating long-term pharmacotherapy. Acknowledging this informed engagement, and structuring the consultation around the four-phase framework above, tends to produce far better adherence and outcomes than the conventional "your cholesterol is high, here is a statin" interaction. The patients who genuinely need statins benefit from the same structured framing — they understand why, on the basis of which evidence, with what expected effect size, and what the alternatives would have been.

Communicating cardiovascular risk — a short section on saying it out loud

Everything above is about getting the right answer. This is about the last two minutes of the consultation, where a correct answer is delivered badly and the patient leaves either falsely reassured or too frightened to start. It is placed last because it applies to every decision above it.

1. Relative risk sounds like a decision. Absolute risk is one. The same finding stated three ways: "a 7% increase in muscle symptoms"; "an extra 11 events per 1,000 person-years"; "about one extra person in a hundred, per year, will get muscle aches they would not otherwise have had". All three describe the CTT year-one figure. Only the third gives the patient something to weigh. The rule that survives contact with a busy clinic: never state a relative risk without the absolute alongside it, in either direction. This applies as much to benefits as to harms — quoting a relative risk reduction for a statin while giving harms in absolute terms is the mirror-image error, and it is common.
2. Give both arms, not one. "This reduces your risk by a third" is unanswerable. "Out of 100 people like you, about 8 would have an event in the next ten years without treatment and about 5 or 6 with it" can be agreed or disagreed with. Numbers that cannot be argued with are numbers that cannot be consented to.
3. Use one denominator and keep it. Switching between "1 in 15", "7%" and "11 per 1,000" inside one conversation is a common and entirely avoidable source of confusion. Pick a natural frequency — out of 100, or out of 1,000 — and hold it for benefits, harms and everything else in the discussion.
4. NNT is useful and routinely over-interpreted. A number needed to treat is only meaningful with its time horizon and its population attached: an NNT of 40 over five years in secondary prevention is a different proposition from an NNT of 40 over ten years in primary prevention. Quoted bare, it invites the patient to conclude that thirty-nine people took a tablet for nothing — which is not what it means, since nobody knows in advance who the one is, and the same logic would abolish seatbelts.
5. Draw it if you can. An icon array — 100 figures with the affected ones shaded — consistently outperforms spoken percentages, and works best for people with lower numeracy, which is precisely the group percentages fail. The essential feature is that the whole denominator is visible: the unaffected 92 are on the page rather than implied. If drawing is not practical, saying "out of a hundred people in your position" does much of the same work.
6. Choose the time horizon deliberately, and say which one you chose. QRISK3 gives ten years. A ten-year estimate can look deceptively low in a 40-year-old because short-term absolute risk is dominated by age — that is a property of the horizon, not a defect in the tool. The 2026 ACC/AHA guideline's PREVENT model reports 10-year and 30-year estimates for this reason. Lifetime and 30-year framings are more informative in younger patients and more likely to prompt action; ten-year framings are more relevant to an older patient's immediate decision. Both are legitimate. Presenting one without naming it as a choice is not.
7. When they arrive already frightened. An increasingly common consultation: the patient has read that statins cause dementia, or that cholesterol was never the problem. Contradicting the source directly tends to entrench it. What works better is to ask what they read and take it seriously as a question; to concede the true part, since most such claims contain one; to give the absolute numbers on both sides; and to name the decision as theirs. It is also worth saying plainly that the symptom they are worried about is real if it happens — the nocebo literature is easy to deliver as an accusation, and delivered that way it ends the conversation.
8. Say the uncertainty. A risk score is a population estimate applied to one person, and it carries a confidence interval that is rarely mentioned. Alongside it, as covered in chapter 2, the panel that fed the score has its own within-person variation of roughly 9% for LDL-C and 20–25% for triglycerides. Stating that a QRISK3 of 9.4% and one of 10.6% should not be treated as meaningfully different on the strength of the numbers alone costs ten seconds and prevents a decision being made on the second decimal place of a number that does not have one.

Important — Not Medical Advice

This tool provides general educational information based on published clinical evidence. It is not a substitute for medical consultation. Cholesterol and cardiovascular health management should always be supervised by your GP or specialist, particularly if you have existing cardiovascular disease, diabetes, familial hypercholesterolaemia, are taking prescription medications, are pregnant or breastfeeding, or have any underlying health conditions. If your triglycerides exceed 5.6 mmol/L there is a risk of pancreatitis — consult your doctor urgently. Supplements may interact with medications. Longevity-tier compounds (NMNH, Apigenin, Urolithin A, TMG) are early-stage interventions with limited long-term human safety data — discuss with a clinician familiar with the literature before starting. Statin alternatives (bempedoic acid, fenofibrate, PCSK9 inhibitors, inclisiran, icosapent ethyl) are prescription medications requiring medical supervision. Shop links lead to Amazon UK search results — these are not affiliate links, purely for convenience.